1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Bladder cancer

Signatera for detecting molecular residual disease from solid tumour cancers

Medtech innovation briefing [MIB307] Published: 04 October 2022

  • Overview
  • Summary
  • The technology
  • Regulatory information
  • Equality considerations
  • Clinical and technical evidence
  • Expert comments
  • Expert commentators
  • Development of this briefing
Download (PDF)

Advice

  • Next

NICE has developed a medtech innovation briefing (MIB) on Signatera for detecting molecular residual disease from solid tumour cancers.

What are MIBs?


  • Next